What is Idhifa used to treat?
Medically reviewed by Drugs.com. Last updated on Sep 30, 2020.
Idhifa (enasidenib) is used to treat adult patients with relapsed (has returned after initial treatment) or refractory (has not responded to treatment) acute myeloid leukemia (AML) who have a specific genetic mutation.
Idhifa is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML. IDH2 gene mutations may lead to immature blood cells becoming cancerous and dividing uncontrollably, causing AML.
Related Medical Questions
- How does Idhifa work in acute myeloid leukemia (AML)?
- How long does it take for Idhifa to start working?
- Can Idhifa cause differentiation syndrome?
- Is Venclexta (venetoclax) chemotherapy?
- How long do you take Venclexta for?
- How effective is Venclexta?
- How is Venclexta (venetoclax) used for AML?
- How does Venclexta work?
- What type of cancer is Daurismo (glasdegib) used to treat?
- What type of leukemia is Xospata (gilteritinib) used to treat?
- What is Tibsovo used to treat?
- What is Rydapt used to treat?
- Idhifa Information for Consumers
- Idhifa Information for Healthcare Professionals (includes dosage details)
- Side Effects of Idhifa (detailed)